 |
|
|
 |
|
Study Questions 'Off-Label' Use of Antipsychotics
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 | 3 The study authors called for more head-to-head trials of the drugs.
"The clearest finding was that the quality of evidence for the most common uses was not very clear-cut, which doesn't prove the case that these aren't appropriate to consider in individual patients. But it does say that given the amount of use they're getting, we need some better research to try to clarify how to identify the right patients to get these drugs," Atkins said.
But Corcoran and others called for a different approach.
Text Continues Below

"Our sense is not more head-to-head trials but the need to develop other kinds of treatments for disorders other than psychosis, drugs that are safer, more appropriate, using rationale drug design," she said.
More information
View the full report at AHRQ.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 1/19/2007
|
 |

SOURCES: David Atkins, M.D., chief medical officer, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, Md.; Julio Licinio, M.D., chairman, department of psychiatry and behavioral sciences, University of Miami Miller School of Medicine; Cheryl Corcoran, M.D., assistant professor of psychiatry, Columbia University, and researcher in schizophrenia, New York State Psychiatric Institute, New York City; Jan. 17, 2007, Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics, Agency for Healthcare Research and Quality
|